Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.51 |
| ▸ | ANPEP | P15144 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938109 | 1.00 | MMP2 (0.51) | MMP2ANPEPALDH1A1POLBCA12 | |
| SCHEMBL14939265 | 1.00 | MMP2 (0.51) | MMP2ANPEPALDH1A1POLBCA12 | |
| SCHEMBL14937927 | 0.83 | MMP2 (0.45) | MMP2ANPEPALDH1A1 | |
| SCHEMBL14939407 | 0.83 | MMP2 (0.45) | MMP2ANPEPALDH1A1 | |
| SCHEMBL3476452 | 0.82 | MMP2 (0.53) | MMP2ANPEPALDH1A1CA12CA1 | |
| SCHEMBL21702575 | 0.77 | MMP2 (0.49) | MMP2ANPEPALDH1A1CA12CA1 | |
| SCHEMBL489252 | 0.76 | MMP2 (0.48) | MMP2ANPEPALDH1A1POLB | |
| SCHEMBL1154972 | 0.76 | MMP2 (0.48) | MMP2ANPEPALDH1A1POLB | |
| SCHEMBL7805563 | 0.76 | MMP2 (0.48) | MMP2ANPEPALDH1A1POLB | |
| SCHEMBL5058842 | 0.76 | MMP2 (0.48) | MMP2ANPEPALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123512-A1 | PROCESS FOR THE PREPARATION OF PROLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123512-A1 | PROCESS FOR THE PREPARATION OF PROLINE DERIVATIVES | CTSS, CTSV, CTSZ | MMP2 83/4885ANPEP 71/4885ALDH1A1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.